[ad_1]
[Transmisión en vivo hoy]
Zhou Keping, Senior Vice President of China Asset Management Equity Investment Department: Job return is above 100%, how to do it?
Changsheng Fund Guo Kun shared: The latest Kun-style investment deduction, how to choose the basic growth stocks?
Xu Xiaoyong, Deputy CEO and Chief Investment Officer of Chang’an Fund: After the crash, does the opportunity come? How to layout?
Essence Securities Chen Guo: Is the bull still at the time of the fourth major divergence of A-shares in the year?
Yin Ruizhe, Chief Fixed Income Analyst at China Merchants Securities: Unfavorable Gaming Trends
Ye Shangzhi, Chief Strategist at First Shanghai Securities: There are staggered peaks in the market (Golden Unicorn analyst), how to trade the Hong Kong stock market outlook?
Depression included in the physical examination of students and pregnant women: or open a list of listed companies related to a market size of 100 billion
Lu Lin Financial Association
Caixie News, September 14, recently, the official website of the National Health Commission published the “Work plan to explore special services for the prevention and treatment of depression.” The “Plan” requires that 80% of the pilot areas know the knowledge of depression prevention in 2022 and seek medical treatment for depression. The rate has increased by 50%, the rate of treatment has increased by 30%, and the rate of recognition of depression by physicians in non-psychiatric hospitals has increased by 50%.
The program also expanded the specific scope of screening for depression. Several high schools, colleges, and universities incorporate depression screening into the content of student health exams while incorporating screening for depression during pregnancy and childbirth into routine pregnancy screening and postpartum visits.
Depression is becoming the second leading cause of human death after cancer. An estimated 350 million people around the world are sick. According to the data published in the article “The Lancet Psychiatry” in 2019 “The lifetime prevalence of depression in China is 6.9%”, it can be estimated that there are more than 95 million patients with depression in China.
The Antidepressant Drug Market Research Report (2018) released by Minai in 2019 shows that in 2018, the sales of antidepressant drugs in the public medical institution market in China were 8.128 billion yuan, and the sales revenue in 2018 they increased 19.13% year-on-year. According to industry experts, with the increase in consultation rate and treatment rate, China’s antidepressant drug market expansion is very safe, and the antidepressant drug market has a bright future.
List of related listed companies:
Tasly： The new class 1 chemical drug for the treatment of depression, JS1-1-01, “Notice of approval of clinical drug trials” has been approved and clinical trials will start in the near future;
Fosun Pharma: Amitriptyline hydrochloride tablets are tricyclic antidepressants, mainly used to treat agonistic anxiety or depression;
Qianyuan Pharmaceutical: Fluoxetine hydrochloride capsules are suitable for depression, obsessive compulsive disorder and bulimia nervosa;
Pinnacle Group: Paroxetine hydrochloride tablets are used to treat depression, obsessive compulsive disorder, etc .;
Huahai Pharmaceutical: Sertraline hydrochloride tablets are mainly used to treat symptoms related to depression and obsessive compulsive disorder;
Foreword: Bupropion hydrochloride sustained-release tablets are suitable for the treatment of moderate to severe depression and seasonal affective disorder, and are approved by the US FDA.
Kelun Pharmaceutical: Citalopram hydrobromide capsules are used primarily for the treatment of depression;
Renfu Medicine： Desvenlafaxine sustained release tablets for the treatment of depression, approved by the US FDA number.
Hengrui Medicine: Esketamine hydrochloride injection can be used for surgical analgesia, sedation, and the treatment of major depression.
Sina Statement: Sina.com publishes this article for the purpose of conveying more information and does not mean that I agree with their views or confirm their description. The content of the article is for reference only and does not constitute investment advice. Investors trade accordingly at their own risk.
Massive information, accurate interpretation, all in the Sina Finance APP
Editor in charge: Zhang Yi
